Capital Asset Advisory Services LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,434 shares of the medical research company’s stock after buying an additional 76 shares during the period. Capital Asset Advisory Services LLC’s holdings in Amgen were worth $323,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. Dixon Hughes Goodman Wealth Advisors LLC acquired a new stake in Amgen in the 4th quarter valued at $26,000. Econ Financial Services Corp acquired a new stake in shares of Amgen in the fourth quarter valued at about $34,000. Strategic Asset Management LLC purchased a new stake in shares of Amgen during the 3rd quarter valued at about $37,000. Level Financial Advisors Inc. acquired a new position in Amgen during the 4th quarter worth approximately $39,000. Finally, Bell Investment Advisors Inc acquired a new position in shares of Amgen during the third quarter worth $52,000. 74.53% of the stock is currently owned by institutional investors and hedge funds.
Several research firms recently issued reports on AMGN. Wells Fargo & Company lifted their price target on shares of Amgen from $210.00 to $250.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 9th. Oppenheimer boosted their price target on Amgen from $272.00 to $285.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 9th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 5th. Bank of America downgraded shares of Amgen from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $285.00 to $255.00 in a research report on Wednesday, January 5th. Finally, Royal Bank of Canada increased their price target on shares of Amgen from $216.00 to $218.00 and gave the stock a “sector perform” rating in a research report on Tuesday, December 21st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $235.24.
Amgen (NASDAQ:AMGN – Get Rating) last announced its earnings results on Monday, February 7th. The medical research company reported $4.36 EPS for the quarter, topping the consensus estimate of $4.14 by $0.22. The company had revenue of $6.85 billion during the quarter, compared to analysts’ expectations of $6.87 billion. Amgen had a net margin of 22.68% and a return on equity of 120.59%. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period last year, the company posted $3.81 earnings per share. As a group, research analysts anticipate that Amgen Inc. will post 17.6 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Stockholders of record on Tuesday, May 17th will be issued a $1.94 dividend. The ex-dividend date is Monday, May 16th. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.08%. Amgen’s payout ratio is currently 75.27%.
Amgen Company Profile (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.